TY - JOUR T1 - Gait speed and prognosis in patients with idiopathic pulmonary fibrosis: a prospective cohort study JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01186-2018 SP - 1801186 AU - Claire M. Nolan AU - Matthew Maddocks AU - Toby M. Maher AU - Winston Banya AU - Suhani Patel AU - Ruth E. Barker AU - Sarah E. Jones AU - Peter George AU - Paul Cullinan AU - William D.-C. Man Y1 - 2018/01/01 UR - http://erj.ersjournals.com/content/early/2018/11/08/13993003.01186-2018.abstract N2 - The four metre gait speed (4 MGS), a simple physical performance measure and surrogate marker of frailty, consistently predicts adverse prognosis in older adults. We hypothesised that 4 MGS could predict all-cause mortality and non-elective hospitalisation in patients with idiopathic pulmonary fibrosis (IPF).4 MGS and lung function were measured at baseline in 130 outpatients newly diagnosed with IPF. Survival status and non-elective hospital admissions were recorded over one year. We assessed the predictive value of 4 MGS (as a continuous variable and as a binary variable: slow versus preserved 4 MGS) by calculating hazard ratios (HR) using Cox proportional regression, adjusting for potential confounding variables. Receiver Operating Characteristic curves assessed discrimination between the multivariable regression models and established prognostic indices.Continuous 4 MGS and slow 4 MGS were independent predictors of all-cause mortality (4 MGS: HR 0.03 (0.01–0.31), p=0.004; slow 4 MGS: 2.63 (1.01–6.87), p=0.049) and hospitalisation (4 MGS: HR 0.02 (0.01–0.14), p<0.001; slow 4 MGS: 2.76 (1.16–6.58), p=0.02). Multivariable models incorporating 4 MGS or slow 4 MGS had better discrimination for predicting mortality than either the Gender Age Physiology index or Composite Physiologic Index.In patients with IPF, 4 MGS is an independent predictor of all-cause mortality and non-elective hospitalisation.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Ms. Nolan has nothing to disclose.Conflict of interest: Dr. Maddocks reports grants from NIHR, outside the submitted work.Conflict of interest: TMM has, via his institution, received industry-academic funding from GlaxoSmithKline R&D and UCB and has received consultancy or speakers fees from Apellis, Astra Zeneca, aTyr Pharma, Bayer, Biogen Idec, Boehringer Ingelheim, Galapagos, GlaxoSmithKline R&D, Indalo, Pliant, ProMetic, Roche, Samumed and UCB.Conflict of interest: Mr. Banya has nothing to disclose.Conflict of interest: Miss. Patel has nothing to disclose.Conflict of interest: Ms. Barker has nothing to disclose.Conflict of interest: Dr. Jones has nothing to disclose.Conflict of interest: Dr. George reports personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Roche Pharmacueticals, outside the submitted work.Conflict of interest: Dr. Cullinan has nothing to disclose.Conflict of interest: Dr. Man reports grants from National Institute for Health Research, during the conduct of the study; grants from Pfizer, non-financial support from GSK, personal fees from Mundipharma, personal fees from Novartis, outside the submitted work. ER -